Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Annual Pap Tests Are a Thing of the Past

By LabMedica International staff writers
Posted on 21 Nov 2012
New guidelines by The American College of Obstetricians and Gynecologists (ACOG; Washington, DC, USA) recommend that women should be normally screened for cervical cancer every three to five years at most.

According to the new guidelines, women under the age of 21, even if they have had sexual intercourse, should not be tested for cervical cancer or human papillomavirus (HPV). More...
This is because invasive cervical cancer is unusual in females younger than 21, even though HPV is common among sexually active teens. Most cervical abnormalities that are associated with HPV infection typically clear up on their own, making no treatment necessary. The College recommends that women ages 21 to 29 should no longer be tested for cervical cancer every two years, but once every three years.


Women aged 30 to 65 will see the biggest change in their screening guidelines. If they have negative results, they will be co-tested with the Pap test (the traditional or liquid-based method) along with HPV test once every five years. If HPV screening is not accessible, a Pap test by itself is sufficient once every three years.

Women older than 65 should no longer receive screening for cervical cancer if they have no history of cervical cancer; no history of cervical intraepithelial neoplasia (CIN) 2 or CIN 3; no history of adenocarcinoma in situ; if they have had three consecutive negative Pap test results, or two consecutive negative co-test results within the past 10 years, with the most recent test within the previous five years. Women, no matter what age, should discontinue routine screening if they have no history of CIN 2 or CIN 3, and who have had a hysterectomy with removal of the cervix (total hysterectomy).

Additionally, HPV-vaccinated women should follow the same guidelines as those who are unvaccinated. The recommendations are not meant for women who are immune-compromised, HIV-positive, or were exposed to diethylstilbestrol (DES) in utero. These females may need more to be tested more often. The new guidelines were published in the November 2012 issue of Obstetrics & Gynecology, and they are similar to the recommendations announced by the American Society for Colposcopy and Cervical Pathology (Frederick, MD, USA), the American Cancer Society, and other medical associations earlier in 2012.

“These recommendation changes are significant for physicians and patients alike. It will take some time and a lot of effort to re-educate everyone that the annual Pap is no longer the standard of care. It is critical, however, that women understand that their annual well-woman visit is still very important for many other aspects of their health care,” said David Chelmow, MD, who led the development of the ACOG guidelines.

Related Links:
The American College of Obstetricians and Gynecologists
American Society for Colposcopy and Cervical Pathology



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.